Key result
Tumor necrosis factor-alpha inhibits growth hormone-inducible Spi 2.1 and IGF-I promoter activity in hepatocytes via an NF-kappaB-mediated mechanism, specifically involving p65.
The inhibitory effects of TNF on GH-inducible Spi 2.1 and IGF-I promoter activity in hepatocytes are mediated by NFkappaB, particularly the p65 subunit.
Findings from hepatocyte cultures are hypothesis-generating for inflammation-induced GH resistance; prospective animal studies needed before clinical consideration.
TNF inhibits serine protease inhibitor 2.1 (Spi 2.1) and IGF-I gene expression by GH in CWSV-1 hepatocytes. The current study describes construction of a GH-inducible IGF-I promoter construct and investigates mechanisms by which TNF and nuclear factor-kappaB (NFkappaB) inhibit GH-inducible gene expression. CWSV-1 cells were transfected with GH-inducible Spi 2.1 or IGF-I promoter luciferase constructs, incubated with TNF signaling inhibitors (fumonisin B1 for sphingomyelinase and SP600125 for c-Jun N-terminal kinase), treated with or without TNF, and then stimulated with recombinant human GH. The 5- to 6-fold induction of Spi 2.1 and IGF-I promoter activity by GH was inhibited by TNF. Neither fumonisin B1 nor SP600125 prevented the inhibitory effects of TNF on GH-inducible promoter activity. Dominant-negative inhibitor-kappaBalpha (IkappaBalpha) expression vectors (IkappaBalphaS/A or IkappaBalphaTrunc), p65 and p50 expression vectors, and p65 deletion constructs were used to investigate the NFkappaB pathway. IkappaBalphaS/A and IkappaBalphaTrunc ameliorated the inhibitory effects of TNF on GH-inducible Spi 2.1 and IGF-I promoter activity. Cotransfection of CWSV-1 cells with expression vectors for p65 alone or p50 and p65 together inhibited GH-inducible Spi 2.1 and IGF-I promoter activity. Cotransfection with a C-terminal p65 deletion (1-450) enhanced GH-inducible promoter activity, whereas the N-terminal deletion (31-551) was inhibitory for IGF-I but not Spi 2.1. Cycloheximide did not antagonize the inhibitory effects of TNF on GH-inducible IGF-I expression. We conclude the inhibitory effects of TNF on GH-inducible promoter activity are mediated by NFkappaB, especially p65, by a mechanism that does not require protein synthesis.
No takes yet. Share an insight, caveat, or question.
Buzzelli et al. (2008) studied this question. Tumor Necrosis Factor-alpha (TNF) and NF-kappaB constructs was evaluated on GH-inducible Spi 2.1 and IGF-I promoter activity. Tumor necrosis factor-alpha inhibits growth hormone-inducible Spi 2.1 and IGF-I promoter activity in hepatocytes via an NF-kappaB-mediated mechanism, specifically involving p65.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: